
Makes Quality simpler and release faster by giving Operations one global Quality system and, through Smart Release, a path towards risk-based, AI-supported review by exception over time.
The role owns the global Quality Management System (QMS), Complaints and Training governance within the Rare Disease Unit (RDU), setting one global standard for each process so that every team and site works the same way and learns from the same evidence. It is the business owner of Smart Release, accountable for its vision, roadmap, adoption and benefits.
Locations - Dublin, Athlone or Cork, Ireland
Key accountabilities
Lead Smart Release so that release moves, over time, towards review by exception
Give Quality Operations one simple global QMS
AI compliance in QMS
Lead a capable, inspection-ready global team
You will need to have:
Degree in pharmacy, science, engineering or a related discipline; advanced degree preferred
Extensive senior Quality leadership in a global, highly regulated biopharmaceutical setting
Proven leadership of global Quality Systems and Complaints, including regulatory inspections
Led a comparable shift: global process simplification or release redesign through a matrix
Technical expertise in QMS, complaints, risk management, CAPA, change control and data integrity, end-to-end disposition and release across manufacturing, testing and external supply
Enough data and AI fluency to shape use cases and challenge AI outputs
20-Oct-2026
Our mission is to build an inclusive and equitable environment. We want people to feel they belong at AstraZeneca and Alexion, starting with our recruitment process. We welcome and consider applications from all qualified candidates, regardless of characteristics. We offer reasonable adjustments/accommodations to help all candidates to perform at their best. If you have a need for any adjustments/accommodations, please complete the section in the application form.

Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community. We are driven by a mission to change what it means to live with a rare disease.
A leader in rare disease for more than three decades and today continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities.
As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally.
GL/NP/0116
GL/NP/0095
Community Guidelines: https://bit.ly/39x9gqy